# Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

> **NCT04709458** · PHASE1 · UNKNOWN · sponsor: **Taiga Biotechnologies, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Myelofibrosis
- Acute Myelogenous Leukemia

## Interventions

- **BIOLOGICAL:** TBX-2400

## Key facts

- **NCT ID:** NCT04709458
- **Lead sponsor:** Taiga Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-08-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04709458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04709458, "Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04709458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*